about us

corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.

leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.

corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy

mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.

delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.

treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
our pipeline

clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.

publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.

novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
patient-forward
news and media

media gallery

Featured Stories
investor relations

press releases

corporate presentation

events

annual reports

sec filings

stock information

corporate governance

faq

email alerts

NASDAQ: current stock price

15.80

0.95

last update 6/19/2017 12:00AM
careers

working with us

our locations

current job listings

View All

press releases

June 13, 2017

Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference

June 08, 2017

First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevaciz...

June 05, 2017

Health Care Service Corporation Issues Positive Coverage Decision for Optune

June 02, 2017

Novocure to Present at the JMP Securities 2017 Life Sciences Conference

May 15, 2017

Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma

May 11, 2017

Martin J. Madden Joins Novocure Board of Directors

May 08, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Severa...

May 04, 2017

Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Glio...

May 01, 2017

Novocure to Present at Three Upcoming Investor Conferences in May

May 01, 2017

Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Qua...

April 27, 2017

Novocure Reports First Quarter 2017 Financial Results and Provides Company Update

April 19, 2017

Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurolo...

April 17, 2017

CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line...

April 02, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Ye...

March 31, 2017

Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent...

March 31, 2017

Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine...

March 31, 2017

Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with St...

March 28, 2017

Novocure to Report First Quarter 2017 Financial Results

March 28, 2017

Novocure to Present at the 16th Annual Needham & Company Healthcare Conference

March 20, 2017

Novocure Receives MHLW Approval for Second Generation Optune® in Japan

March 01, 2017

Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting...

February 23, 2017

Novocure Announces Departure of Chief Commercial Officer

February 23, 2017

Novocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update

February 15, 2017

First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for...

February 07, 2017

Novocure to Participate in the BIO 2017 CEO & Investor Conference

January 24, 2017

Novocure to Participate in Noble Capital Markets’ 13th Annual Investor Conference

January 19, 2017

Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.

January 10, 2017

Novocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics

January 10, 2017

Novocure to Report Fourth Quarter and Full Year 2016 Financial Results

December 19, 2016

Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblas...

December 15, 2016

Novocure to Participate in 35th Annual J.P. Morgan Healthcare Conference

December 12, 2016

Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fiel...

December 12, 2016

Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclita...

December 08, 2016

Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016

November 18, 2016

Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagn...

November 17, 2016

Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields P...

November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st ...

November 07, 2016

Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of th...

November 03, 2016

United Healthcare Issues Positive Coverage Decision for Optune

November 02, 2016

Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update

November 01, 2016

Novocure Recognizes National Family Caregivers Month by Supporting GBM Heroes Event

October 12, 2016

Novocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial

September 30, 2016

CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results

September 30, 2016

Novocure to Report Third Quarter 2016 Financial Results

September 19, 2016

CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in ...

September 15, 2016

Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academ...

September 14, 2016

Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields

September 12, 2016

Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagn...

September 01, 2016

International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Pac...

August 16, 2016

Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA A...

August 08, 2016

Novocure to Present at Upcoming Investor Conferences

July 28, 2016

Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update

July 28, 2016

Novocure to Host Research and Development Day on Dec. 12, 2016

July 26, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

July 13, 2016

Novocure Receives FDA Approval for Second Generation Optune System

June 30, 2016

Novocure to Report Second Quarter 2016 Financial Results

June 30, 2016

Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors

press kit

View our press kit to learn more about our company. For interview requests, please contact media@novocure.com.

Patient B-roll

Download

MOA B-roll

Download

Treatment Overview Video - Scientific

Download

Treatment Overview Video - General Public

Download

Novocure Annual Report

Download

Understanding Optune Brochure

Download

Logos

Download

Optune System infographic

Download

Novocure media gallery

Click through our media gallery to view photos of our patients, our therapy, our employees and more.

Launch Gallery

featured stories

Learn more about our company and our mission.

Learn More

Picture

2000 Novocure research center opens

about us
- corporate timeline Professor Yoram Palti founded Novocure in 2000. We have since accomplished many significant milestones.
- leadership Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
- corporate presentation We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields.
our therapy
- mechanism of action Our proprietary technology – Tumor Treating Fields – disrupts cell division through physical interactions with key molecules during mitosis.
- delivery method We deliver Tumor Treating Fields through a noninvasive, portable medical device that targets solid tumors with no known systemic toxicities.
- treating cancer with electric fields Treatment with Tumor Treating Fields has become a fourth modality in cancer care.
our pipeline
- clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors.
- publications We have more than 15 years of research and multiple peer-reviewed publications with pre-clinical data in 15 cancer types and clinical data in eight cancer types.
- novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
patient-forward
news and media
- media gallery
- Featured Stories
investor relations
careers

news and media center

press releases

press kit

Patient B-roll

MOA B-roll

Treatment Overview Video - Scientific

Treatment Overview Video - General Public

Novocure Annual Report

Understanding Optune Brochure

Logos

Optune System infographic

Novocure media gallery

featured stories

2000 Novocure research center opens